Abstract:Background: It is universally accepted that change of specific proteins is of great significance in the development of tumor and post translational modification (PTM) is a major way to modify protein activity. O-GlcNAcylation,as one of post translational modifications of proteins regulated by OGT and OGA, has linked glucose metabolism disorders with the malignancies. Numerous studies have demonstrated the aberrant activation of O-GlcNAcylation and OGT in tumors. The aim of this study is to investigate the potential role and underlying mechanisms of O-GlcNAcylation in HCC progression.Methods: The level of O-GlcNAcylation was detected by IHC staining and western blot. Function of O-GlcNAcylationin HCC proliferation was investigated by CCK8, BrdU, colony forming, cell cycle assay and subcutaneous xenograft tumor model. Scratch healing, transwell assay and 3D spheroid invasion assay were employed for testing metastatic ability of cells. Moreover, Mass-spectrum and co-IP assay were performed to explore novel OGT binding proteins.Results: Total O-GlcNAcylation level of proteins was markedly overexpressed in HCC compared to adjacent normal tissues and the upregulation of O-GlcNAcylation was associated with poor outcome of patients. The results of in vitro and vivoexperiments showed consistently that high level of O-GlcNAcylation could promote HCC proliferation and metastasis. A large number of studies show that the O-GlcNAcylation of key protein is the crucial step for O-GlcNAcylation regulation in tumor. We examined the mass spectrum results of HCC cell line IP-OGT samples and found 214 eligible candidates. Then GO annotation and the KEGG pathway analysis was employed to try to find targets within the tumor related range. Among the potential candidates which could related to tumor transcription misregulation, we find out that SIX1 which could regulate a series of downstream oncogenic factors and glycolysis related genes including c-myc, cyclin D1, GLUT1 and ENO1 to be a possible effect factor of O-GlcNAcylation. The further data demonstrated that SIX1 was modified by O-GlcNAcylation, and O-GlcNAcylation could maintain the high expression status of SIX1 by inhibiting itsubiquitination degradation.Conclusions: In conclusion, our data suggest that O-GlcNAcylation significantly increased in HCC compared to normal tissues. The high expression of O-GlcNAcylation could be an independent prognostic factor in HCC and was associated with poor outcome of patients. Further, we find out SIX1 was the underlying executor of O-GlcNAcylation in HCC. By inhibiting SIX1 ubiquitination, O-GlcNAcylation could maintain SIX1 and its downstream factors in a high level persistently and therefore promote HCC progression. Here in our study, we for the first time identified a neo-posttranslation O-GlcNAcytion modification pathway in HCC, which could provide potential therapy for HCC treatment.Citation Format: Yongzhan Nie, Yi Chu, Daiming Fan, Mingzuo Jiang, Nan Wu, Hongwei Li. Hyper O-GlcNAcylation plays an oncogenic role in hepatocellular cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 848.

O-GlcNAcylation of RACK1 Promotes Hepatocellular Carcinogenesis

Regulation of cancer metabolism by O-GlcNAcylation

Ribosomal RACK1 Promotes Chemoresistance and Growth in Human Hepatocellular Carcinoma

Abstract 848: Hyper O-GlcNAcylation Plays an Oncogenic Role in Hepatocellular Cancer

RACK1 Promotes Self-Renewal and Chemoresistance of Cancer Stem Cells in Human Hepatocellular Carcinoma through Stabilizing Nanog

O-GlcNAcylation Promotes Pancreatic Tumor Growth by Regulating Malate Dehydrogenase 1

RANBP2 Activates O-GlcNAcylation Through Inducing CEBPα-Dependent OGA Downregulation to Promote Hepatocellular Carcinoma Malignant Phenotypes

Low Expression of RACK1 is Associated with Metastasis and Worse Prognosis in Cholangiocarcinoma

Gluconeogenic enzyme PCK1 deficiency promotes CHK2 O-GlcNAcylation and hepatocellular carcinoma growth upon glucose deprivation

O-GlcNAc modified-TIP60/KAT5 is required for PCK1 deficiency-induced HCC metastasis

O-GlcNAcylation of E3 ubiquitin ligase SKP2 promotes hepatocellular carcinoma proliferation

RACK1 Acts As a Potential Tumor Promoter in Colorectal Cancer

Loss of RACK1 Promotes Glutamine Addiction Via Activating AKT/mTOR/ASCT2 Axis to Facilitate Tumor Growth in Gastric Cancer

Receptor for activated C kinase 1 promotes hepatocellular carcinoma growth by enhancing mitogen-activated protein kinase kinase 7 activity.

O-GlcNAcylation Facilitates the Interaction Between Keratin 18 and Isocitrate Dehydrogenases and Potentially Influencing Cholangiocarcinoma Progression

MAPK/ERK Signaling Pathway-Induced Hyper-O-glcnacylation Enhances Cancer Malignancy.

Overexpression of Rack1 Promotes Metastasis by Enhancing Epithelial-Mesenchymal Transition and Predicts Poor Prognosis in Human Glioma

RACK1 promotes the occurrence and progression of cervical carcinoma

O-GlcNAcylation Mediates Metastasis of Cholangiocarcinoma Through FOXO3 and MAN1A1

O-GlcNAcylation of Keratin 18 Coordinates TCA Cycle to Promote Cholangiocarcinoma Progression

O‐GlcNAcylation Promotes the Migratory Ability of Hepatocellular Carcinoma Cells Via Regulating FOXA2 Stability and Transcriptional Activity